CARCINOMICS AND CLINICAL COMMUNICATIONS PUBLISHES OUTCOMES OF RESEARCH
from the fields of RNaOmics, proteomics, metabolomics, genomics, epigenomics, pharmacogenomics, etc. related to Oncology and closely related subjects
The title of Clinical Communications-Oncology Journal has been changed to CARCINOMICS and Clinical Communications. The journal’s full text is available online at http://www.carcinomics.org
Intravitreal bevacizumab for choroidal metastases secondary to adenocarcinoma of the lung
To present a case of choroidal metastases from lung adenocarcinoma treated with intravitreal bevacizumab prior to external beam radiotherapy and systemic chemotherapy. Retrospective interventional. A ...
Zoledronic acid induces an immune response through increased central memory and effector memory gamma/delta T cells in early and metastatic breast cancer patients
Introduction: Zoledronic acid (ZA) in combination with endocrine therapy (ET) and ovarian ablation yielded a disease-free survival and overall survival advantage in women with estrogen receptor...
View All Articles
Trends among US oncologists in managing patients with nonsmall cell lung carcinoma: 2011-2013
Background: The management of patients with nonsmall cell lung carcinoma (NSCLC) is evolving rapidly. There have been Food and Drug Administration approvals for new therapies or expanded use of...
Dr. Gopala Kovvali
CARCINOMICS and Clinical Communications, a publication of CARCINOMICS Society (USA), is a peer-reviewed online journal with Quarterly print on demand compilation of issues published. The journal’s full text is available online at http://www.carcinomics.org. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.
CARCINOMICS and Clinical Communications operates on “authors pay, readers read free” model to eliminate the barriers between the outcome of good research and the scientific community.
The journal charges US $ 600 (INR 20,000 for authors from Indian sub-continent). Partial waivers can be granted by the Chief Editor. Please send your inquires to editor@CARCINOMICS.ORG before submitting your manuscript.
Members of CARCINOMCIS Society publish free. For membership rates and details, please visit www.CARCINOMICS.NET.
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, ProQuest, TdNet, Wanfang Data